To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 1

Dr. Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic and Steven Lucio, Senior Principal in Pharmacy Solutions at Vizient discuss their insights on the approval, role, and coverage of Aducanumab, the first drug in a new class approved for Alzheimer’s by the FDA’s accelerated approval process.

 

Guest speakers:
Mandy Leonard, PharmD, BCPS
Senior Director of Drug Use Policy and Formulary Management 
Cleveland Clinic

 

Steven Lucio, PharmD, BCPS
Senior Principal in Pharmacy Solutions 
Vizient

 

Moderator:
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence

 

Show Notes:

[01:20 -4:16] How aducanumab fits into the treatment of Alzheimer's disease

[04:17-8:29] Accelerated Approval process and Aducanumab

[08:30-14:38] Aducanumab trials and efficacy

[14:39-17:24] Aducanumab trials and safety

 

Links | Resources:

EMERGE and ENGAGE

 

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Google Podcasts

Spotify

Stitcher

Android

RSS Feed